Diffuse Large B-cell Lymphoma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, Other Drugs), By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies), By End-User (Hospitals & Clinics, Ambulatory care Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 4.82 Billion
CAGR (2026-2031)	8.31%
Fastest Growing Segment	Hospitals & Clinics
Largest Market	North America
Market Size (2031)	USD 7.78 Billion

Market Overview

The Global Diffuse Large B-cell Lymphoma Therapeutics Market will grow from USD 4.82 Billion in 2025 to USD 7.78 Billion by 2031 at a 8.31% CAGR. Diffuse Large B-cell Lymphoma therapeutics comprise pharmaceutical agents and immunotherapies, including monoclonal antibodies and CAR-T cell therapies, designed to treat this aggressive malignancy of B-lymphocytes. The market is primarily driven by the rising prevalence of hematological cancers and an aging global population that is increasingly susceptible to such conditions. Furthermore, the commercialization of novel targeted therapies and bispecific antibodies has significantly widened the treatment landscape. According to the American Cancer Society, in 2025, approximately 80,350 new cases of Non-Hodgkin Lymphoma were projected in the United States, underscoring the critical need for Diffuse Large B-cell Lymphoma interventions as the predominant subtype.

Nevertheless, the exorbitant cost associated with advanced treatment modalities presents a significant challenge that could impede market expansion. The high pricing of next-generation cell therapies often exceeds reimbursement limits, thereby restricting patient access in cost-sensitive healthcare systems. Consequently, financial toxicity and stringent coverage limitations by insurance payers remain major hurdles that could hinder the widespread global adoption of these sophisticated therapeutics.

Key Market Drivers

The proliferation of CAR-T cell therapies and bispecific antibodies is fundamentally reshaping the Global Diffuse Large B-cell Lymphoma Therapeutics Market by offering durable remission potential for patients with refractory disease. This wave of innovation has moved beyond early-stage trials into substantial commercial adoption, driven by the superior efficacy of CD19-targeted modalities over conventional chemotherapy. As clinical confidence grows, the uptake of these novel agents has accelerated significantly, shifting the market toward high-value immunotherapies. For instance, according to Bristol Myers Squibb, in February 2025, global revenues for the CAR-T cell therapy Breyanzi surged by 105% year-over-year to reach $747 million in 2024. This rapid expansion highlights the increasing reliance on advanced biologics. Furthermore, the sector is bolstered by the sustained performance of established cell therapies; according to Gilead Sciences, in February 2025, full-year 2024 sales of Yescarta totaled $1.6 billion, underscoring the deep market penetration and commercial viability of these sophisticated treatment platforms.

Concurrently, the rising global incidence of Diffuse Large B-cell Lymphoma, compounded by rapidly aging demographics, is creating a sustained surge in patient demand for effective therapeutic interventions. As the most prevalent subtype of non-Hodgkin lymphoma, the expanding addressable population pressures healthcare systems to adopt scalable treatment options. The correlation between advanced age and disease susceptibility ensures a steady inflow of new cases, necessitating continuous market supply. According to Incyte, in January 2026, approximately 24,000 people in the United States and 36,000 people in Europe are diagnosed with Diffuse Large B-cell Lymphoma each year. This robust epidemiological burden serves as a foundational driver, guaranteeing long-term demand for therapeutics and incentivizing continued research and development investment into accessible regimens for an increasingly frail patient population.

Download Free Sample Report

Key Market Challenges

The exorbitant cost associated with advanced treatment modalities constitutes a substantial barrier to the expansion of the Global Diffuse Large B-cell Lymphoma Therapeutics Market. While novel immunotherapies offer significant clinical benefits, their high price points frequently create financial toxicity that strains healthcare budgets and exceeds standard reimbursement models. Consequently, hospitals and treatment centers face economic disincentives to adopt these therapies, as the reimbursement provided by insurers often fails to cover the total cost of acquisition, administration, and patient management.

This financial disparity is highlighted by recent data regarding the treatment burden. According to the American Society of Hematology, in 2024, the average Medicare cost for CAR-T cell therapy administered in an inpatient setting was approximately $498,723. Such elevated costs result in stringent coverage limitations and substantial out-of-pocket expenses, thereby restricting patient access to these interventions. Ultimately, these economic pressures limit the volume of patients capable of securing treatment, directly dampening the commercial uptake of these therapeutic agents and slowing the overall revenue growth of the market.

Key Market Trends

The Shift of Treatment Administration to Outpatient Settings is altering care delivery models for Diffuse Large B-cell Lymphoma. This transition is primarily enabled by the approval and uptake of subcutaneously administered bispecific antibodies, which offer a convenient alternative to the complex, inpatient-mandatory logistics of autologous CAR-T cell therapies. By reducing the need for prolonged hospitalization, these off-the-shelf agents alleviate the infrastructure burden on specialized centers and facilitate treatment in community oncology practices. This trend is substantiated by the commercial adoption of such modalities; according to Genmab, February 2025, in the 'Annual Report 2024', global net sales of the subcutaneous bispecific antibody Epkinly reached $281 million in 2024. This robust uptake validates the market's preference for regimens that balance high potency with logistical flexibility, significantly expanding patient access beyond academic medical centers.

Simultaneously, the Integration of Antibody-Drug Conjugates into First-Line Standards is redefining initial patient management, directly challenging the decades-old R-CHOP chemotherapy benchmark. The clinical success of CD79b-targeted agents combined with standard immunochemotherapy has established a new efficacy reference, particularly for high-risk populations who historically faced poor outcomes with conventional regimens alone. This elevation of targeted therapeutics from the salvage setting to frontline care significantly increases the addressable patient volume and market value per treated individual. According to Roche, January 2025, in the 'Finance Report 2024', sales of the antibody-drug conjugate Polivy reached CHF 1.12 billion in 2024, driven primarily by its widespread adoption as a standard-of-care treatment for previously untreated disease. This financial milestone underscores the sector's definitive pivot toward incorporating precision biologics earlier in the treatment paradigm to maximize long-term survival rates.

Segmental Insights

The Hospitals and Clinics segment represents the fastest-growing category within the Global Diffuse Large B-cell Lymphoma Therapeutics Market due to the critical need for specialized administration of complex treatments. Therapies such as CAR-T cell infusions and high-dose chemotherapy regimens require continuous medical supervision to manage potential adverse events effectively. Regulatory guidelines from entities like the US Food and Drug Administration often mandate that these intensive treatments be dispensed in controlled environments to ensure patient safety. Consequently, the reliance on inpatient care for administering these potent therapeutic agents drives the accelerated expansion of this segment.

Regional Insights

North America maintains the leading position in the global diffuse large B-cell lymphoma therapeutics market, driven primarily by the high prevalence of non-Hodgkin lymphoma within the United States. The region benefits from established healthcare infrastructure and the presence of key pharmaceutical manufacturers focusing on oncology. Additionally, the United States Food and Drug Administration facilitates market growth through supportive regulatory pathways for new drug approvals. Comprehensive health insurance coverage further enables patient access to high-cost therapies, ensuring consistent revenue generation for market participants in this geography.

Recent Developments

• In September 2025, AbbVie released updated findings from the Phase 2 EPCORE NHL-6 trial, evaluating the feasibility of outpatient administration for its lymphoma therapy, Epkinly. The study focused on adult patients with relapsed or refractory diffuse large B-cell lymphoma and demonstrated that the safety profile remained manageable without mandatory hospitalization for the first full dose. The data revealed an overall response rate of over 60% in the evaluated cohorts, suggesting that outpatient monitoring could broaden patient access to this bispecific antibody treatment. The company indicated that these results would facilitate further regulatory engagements to potentially optimize the administration protocol of the drug.
• In February 2025, Pfizer announced that the U.S. Food and Drug Administration granted approval for Adcetris in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. This regulatory milestone was supported by data from the Phase 3 ECHELON-3 clinical trial, which showed a statistically significant improvement in overall survival compared to the standard of care. The approval marked a major expansion for the antibody-drug conjugate into the diffuse large B-cell lymphoma therapeutics market, offering a new therapeutic option for patients who are ineligible for stem cell transplants or CAR-T cell therapy.
• In December 2024, AbbVie unveiled significant clinical trial results regarding its bispecific antibody, Epkinly, at the American Society of Hematology Annual Meeting. The presented data from the Phase 1b/2 EPCORE NHL-2 trial demonstrated that combining the therapy with the standard R-CHOP regimen achieved an overall response rate of 100% and a complete response rate of 87% in adult patients with untreated, high-risk diffuse large B-cell lymphoma. These findings highlighted the potential of this subcutaneous T-cell engaging antibody to improve outcomes in frontline treatment settings. The company emphasized that these positive results support the continued expansion of the drug’s clinical development program across various B-cell malignancies.
• In February 2024, Incyte secured exclusive global rights to the diffuse large B-cell lymphoma treatment Monjuvi from its partner MorphoSys. Under the terms of the strategic agreement, Incyte paid a one-time fee of $25 million to obtain full control over the development and commercialization of the anti-CD19 antibody. This transaction occurred shortly before Novartis announced its acquisition of MorphoSys, allowing Incyte to consolidate its assets in the therapeutics market. The deal eliminated future milestone payments and profit-sharing obligations, thereby streamlining the operational structure for the drug, which is approved for use in combination with lenalidomide for relapsed or refractory patients.

Key Market Players

• Gilead Sciences Inc
• Novartis AG
• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd.
• CTI BioPharma Corp.
• Celltrion Healthcare Co. Ltd.
• Bristol Myers Squibb Company
• AbbVie Inc

By Drug Class	By Therapy	By End-User	By Region
Cisplatin Carboplatin 5-fluorouracil Docetaxel Paclitaxel Methotrexate Other Drugs	Targeted Therapy Immunotherapy Chemotherapy Other Therapies	Hospitals & Clinics Ambulatory care Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Diffuse Large B-cell Lymphoma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Diffuse Large B-cell Lymphoma Therapeutics Market, By Drug Class:

• Cisplatin
• Carboplatin
• 5-fluorouracil
• Docetaxel
• Paclitaxel
• Methotrexate
• Other Drugs

• Diffuse Large B-cell Lymphoma Therapeutics Market, By Therapy:

• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Other Therapies

• Diffuse Large B-cell Lymphoma Therapeutics Market, By End-User:

• Hospitals & Clinics
• Ambulatory care Centers
• Others

• Diffuse Large B-cell Lymphoma Therapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE